Changing the Paradigm in HER2-Positive Early Breast Cancer

The DESTINY-Breast11 and DESTINY-Breast05 trials of trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer, but the broad new indications leave questions about sequencing and patient choice. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.